...
首页> 外文期刊>Pakistan journal of medical sciences. >Efficacy and safety of transepithelial collagen crosslinking for progressive keratoconus
【24h】

Efficacy and safety of transepithelial collagen crosslinking for progressive keratoconus

机译:经皮上皮胶原交联治疗进行性圆锥角膜的功效和安全性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: To evaluate the efficacy and safety of transepithelial (TE) collagen cross-linking (CXL) in patients with progressive keratoconus (KC).Methods: This Quasi Experimental Study was conducted at PNS Shifa Naval Hospital, Karachi from June 2015 to June 2016. Sixty eyes of 32 patients who underwent TE CXL for progressive KC from June 2015 to June 2016 were analysed to ascertain efficacy and safety of TE CXL procedure. Statistical analysis of the data was done using SPSS version 17.0.Results: Twenty eight (87.5%) patients underwent TE CXL bilaterally, while 4 (12.5%) underwent unilateral CXL. Mean change in astigmatism, Maximum simulated Keratometry value (Kmax), Spherical equivalent (SE) and Central Corneal Thickness (CCT) were -0.67±0.35D, 1.28±0.64D, -0.58±0.17D and 0.40±7.58μm respectively, from baseline. Mean gain in lines on Snellen’s visual acuity chart was 1.13±0.83 lines. Changes in astigmatism, Kmax and SE were statistically significant (p<0.001), while change in CCT was not statistically significant. The procedure had excellent safety profile, with no major complication till 6 months follow up period.Conclusion: TE CXL is a safe and effective procedure with statistically significant reduction in corneal astigmatism, Kmax and SE with reasonable gain in Snellen’s visual acuity.doi: http://dx.doi.org/10.12669/pjms.325.10922How to cite this:Ameen SS, Mehboob MA, Ali K. Efficacy and safety of transepithelial collagen cross linking for progressive keratoconus. Pak J Med Sci. 2016;32(5):1111-1115. doi: http://dx.doi.org/10.12669/pjms.325.10922This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
机译:目的:评估上皮(TE)胶原交联(CXL)在进行性圆锥角膜(KC)患者中的疗效和安全性。方法:这项准实验研究于2015年6月至2016年6月在卡拉奇PNS Shifa海军医院进行。分析了2015年6月至2016年6月接受TE CXL进行性KC治疗的32例患者的60眼,以确定TE CXL手术的有效性和安全性。使用SPSS 17.0版对数据进行统计分析。结果:二十八例(87.5%)患者接受双侧TE CXL治疗,而4例(12.5%)患者接受单侧CXL治疗。散光的平均变化,最大模拟角膜测量值(Kmax),球等效量(SE)和中央角膜厚度(CCT)分别为-0.67±0.35D,1.28±0.64D,-0.58±0.17D和0.40±7.58μm基线。 Snellen视力表上的平均线条增益为1.13±0.83线条。散光,Kmax和SE的变化具有统计学意义(p <0.001),而CCT的变化无统计学意义。该手术具有良好的安全性,在随访6个月之前没有重大并发症。结论:TE CXL是一种安全有效的手术,其角膜散光,Kmax和SE在统计学上显着降低,Snellen的视敏度得到合理的提高。 ://dx.doi.org/10.12669/pjms.325.10922引用方式:Ameen SS,Mehboob MA,Ali K.经上皮胶原交联用于进行性圆锥角膜的功效和安全性。朴J医学。 2016; 32(5):1111-1115。 doi:http://dx.doi.org/10.12669/pjms.325.10922。这是根据知识共享署名许可(http://creativecommons.org/licenses/by/3.0)条款发布的开放获取文章,只要适当引用了原始作品,便可以在任何介质中不受限制地使用,分发和复制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号